Introduction: Polycythemia vera (PV) is characterized by trilineage blood cell expansion, PV-associated symptoms, and the risk of thromboembolic complications, progression to post-PV myelofibrosis, and acute leukemia. Cytoreductive treatment with hydroxyurea (HU) or ropeginterferon-alpha is approved in EU for the treatment of high-risk patients (pts) with PV. In addition, ruxolitinib (RUX) is approved for HU-intolerant/-resistant PV. However, RUX vs. best available therapy (BAT) has not been investigated as first-line treatment of pts with untreated PV. We hypothesized that RUX may have higher efficacy in such early-line PV pts.
Methods: The clinical trial entitled “Ruxolitinib versus Best Available Therapy in pts with high-risk PV or high-risk ET” (RuxoBEAT; NCT02577926) is a multicenter, open-label, two-arm phase-IIb trial with a target population of 190 pts in each stratum. Crossover from BAT to RUX is possible in eligible pts after 6 months. Pts with PV in the RUX arm received a starting dose of 10 mg BID and may increase their dose up to 20 mg BID. The primary endpoint is the clinicohematologic complete response (CR) rate at month 6, as defined by Barosi et al (Blood 2009), using a strict score of zero for the four symptoms by patient-reported outcome measures (PROM, Table 2) and an adjusted level alpha = 0.005 at a power of 80%. Secondary endpoints include overall response rate (CR+PR), freedom from phlebotomy, changes in blood counts, spleen size, and PROM, using p values descriptively. The interim trial data were recently reviewed by the DMC, and, due to the low likelihood of reaching the primary endpoint (CR rate improvement), the DMC has recommended that the trial should continue without recruitment of new pts. Therefore, this pre-specified interim analysis was performed after 78 (instead of 95) PV pts were randomized 1:1 to RUX vs. BAT. A maximum of 6 weeks of previous PV-directed therapy was allowed. Differences between RUX and BAT at month 6 and between baseline and end of month 6 data for each treatment were calculated using Fisher´s exact test/ McNemar Test (for unpaired/ paired binary variables) or the Mann-Whitney-U test/ Wilcoxon signed-rank test (for unpaired/ paired ordered or continuous variables).
Results: 78 first-line pts (33% were pre-treated for a median of 22 days [range 1-42]) were included in the intention-to-treat set (n=44 vs 34 randomized to RUX vs. BAT, resp.) and analyzed at the 6-month time point. Baseline characteristics are listed in Table 1. In pts on RUX or BAT, CR rates at 6 months were comparable (2.3% and 2.9%, p=1.0), while overall response (CR+PR) rates were 77.3% with RUX and 55.9% with BAT (p=0.054). Also, at month 6 (Table 2), pts on RUX showed significantly lower hematocrit (40.8% vs 42.1%, p=0.046), and PROM symptom points for pruritus (1 vs 4, p=0.001) and fatigue (2.5 vs 5, p=0.031), and a trend towards less headache, abdominal discomfort, and weight loss, while the number of platelets was lower with BAT vs. RUX (254/nl vs 386/nl, p=0.013). There was no difference between RUX and BAT in the number of white blood cells (WBC), spleen size, or other symptoms at this time point.
When each treatment arm was analyzed separately for changes between baseline and month 6, RUX treatment significantly reduced platelet counts, WBC, hemoglobin and hematocrit, phlebotomy rates, spleen size and fraction of pts with splenomegaly (Table 2), and significantly improved PROMs for pruritus, early satiety, and quality of life. During the same time period, BAT significantly reduced platelet counts, WBC, hematocrit, and phlebotomy rates, but failed to impact on hemoglobin, spleen size, fraction of pts with splenomegaly, or any of the symptoms (Table 2).
Safety analysis revealed 301 adverse events (AE) in both assigned treatment groups, including 153 AE in the RUX and 148 AE in the BAT group (11.8% and 8.1% grade ≥3, resp.). There was no significant difference in the percentage of grade ≥3 AE between both groups (p=0.358), and there were no consistent patterns of grade ≥3 AE in either of the two arms.
Conclusion: In this interim analysis, first-line treatment with ruxolitinib for 6 months in high-risk pts with PV led to clinically meaningful improvements in overall response, hemoglobin and hematocrit, phlebotomy rates, splenomegaly, and patient-reported pruritus and fatigue severity, while BAT only improved platelet counts, WBC, hematocrit, and phlebotomy rates, without having an impact on symptoms.
OffLabel Disclosure:
Koschmieder:Squibb: Consultancy, Honoraria; Bayer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; PharmaEssentia: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; RWTH Aachen University: Patents & Royalties: patent issued for a BET inhibitor; CTI Biopharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Imago Bioscience: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Sierra Oncology: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support, Research Funding; AOP Pharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support, Research Funding; Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI BioPharma, Roche, Bayer, GSK, Sierra Oncology, AbbVie, Protagonist, PharmaEssentia: Other: Advisory board; Pfizer, Incyte, Ariad, Novartis, AOP Pharma, Bristol Myers Squibb, Celgene, Geron, Janssen, CTI BioPharma, Roche, Bayer, GSK, Protagonist, MPN Hub, Bedrock, PharmaEssentia: Consultancy; Geron, Janssen, AOP Pharma, Novartis: Research Funding; Novartis, BMS/Celgene, Pfizer, Incyte, AOP Orphan, GSK, AbbVie, MPN Hub, Bedrock, iOMEDICO: Honoraria; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Bristol Meyers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Ariad: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Karthos: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Alexion, Novartis, Bristol Myers Squibb, Incyte, AOP Pharma, CTI BioPharma, Pfizer, Celgene, Janssen, Geron, Roche, AbbVie, GSK, Sierra Oncology, Kartos, Imago Biosciences, MSD, iOMEDICO: Other: Travel/accommodation support; RWTH Aachen University: Patents & Royalties: BET inhibitor; Protagonist: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; GSK: Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support, Research Funding; Geron: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support, Research Funding. Isfort:Hexal: Other: Travel support; Roche: Other: Travel support; Mundipharma: Other: Travel support; Alexion: Other: Travel support; AOP Orphan: Honoraria, Other: Travel support; BMS: Honoraria; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support; GSK: Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support. Teichmann:AOP: Honoraria; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; Boehringer Ingelheim: Honoraria; Sobi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astellas: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; BeiGene: Other: Conference fees; Gilead: Other: Conference fees. Schafhausen:Sobi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support; MSD: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support; Merck Serono: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support; BMS/Celgene: Consultancy, Honoraria, Other: Travel and accomodation support; Blueprint Medicines Corporation: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support; AOP Orphan: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support; Alexion: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support. Heidel:Pfizer: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Research Funding; CTI Biopharma: Consultancy, Honoraria, Research Funding; AOP Orphan: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Kartos: Consultancy, Honoraria. Hochhaus:Bristol Myers Squibb: Consultancy, Research Funding; Pfizer: Research Funding; Incyte: Research Funding; Takeda: Consultancy, Research Funding; Novartis: Consultancy, Research Funding. Griesshammer:Sierra: Consultancy, Honoraria, Speakers Bureau; AstraZeneca: Consultancy, Honoraria, Speakers Bureau; Gilead: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; Roche: Consultancy, Honoraria, Speakers Bureau; Pfizer: Consultancy, Honoraria, Speakers Bureau; AbbVie: Consultancy, Honoraria, Speakers Bureau; BMS: Consultancy, Honoraria, Speakers Bureau; AOP Orphan: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy, Honoraria, Speakers Bureau. Jost:Ariad: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support, Research Funding; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support, Research Funding; Bayer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support, Research Funding; Boehringer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support, Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support, Research Funding; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support, Research Funding; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support, Research Funding; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support, Research Funding; BMS and Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support, Research Funding; Pierre Fabre: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support, Research Funding; Janssen / Johnson & Johnson: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support, Research Funding; MSD: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support, Research Funding. Döhner:Janssen: Consultancy; Abbvie: Consultancy; Astellas: Research Funding; Jazz: Consultancy; Daiichi Sankyo: Consultancy; Roche: Consultancy, Speakers Bureau; Novartis: Consultancy, Research Funding, Speakers Bureau; CTI: Consultancy, Speakers Bureau; Celgene: Consultancy, Research Funding, Speakers Bureau; BMS: Consultancy, Research Funding, Speakers Bureau; Agios: Research Funding. Goethert:Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Consultancy; GlaxoSmithKline: Consultancy; CTI BioPharma: Consultancy; Abbvie: Consultancy; Novartis: Consultancy, Honoraria, Other: travel expenses; AOP Pharma: Consultancy, Honoraria, Other: travel expenses; Pfizer: Consultancy, Honoraria; Incyte: Consultancy, Honoraria, Other: travel expenses; Ariad: Consultancy, Honoraria; Proteros Biostructures: Honoraria; zr pharma&: Honoraria; BMS: Consultancy, Honoraria, Other: travel expenses. Radsak:Bristol Myers Squibb: Other: Travel support; Daiichi Sankyo: Other: Travel support; Novartis: Other: Travel support; Incyte: Honoraria; Takeda: Honoraria; Cogent Biosciences: Honoraria; Corat: Honoraria; JAZZ: Other: Travel support; Novartis: Honoraria, Research Funding; TEVA: Honoraria; Otsuka: Honoraria; Lilly: Honoraria; Abbvie: Honoraria; Pfizer: Honoraria; Beigene: Honoraria; Glaxo Smith Kline: Honoraria; Amgen: Other: Travel support; Bristol Myers Squibb: Honoraria; Abbvie: Other: Travel support; Astellas: Other: Travel support; SOBI: Other: Travel support; AOP: Other: Travel support. Becker:Pierre Fabre Pharma: Consultancy, Honoraria; Servier: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; MSD: Consultancy, Honoraria; Lilly: Consultancy, Honoraria; GSK: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria. Giagounidis:Amgen: Consultancy; Keros Pharmaceuticals: Consultancy; Novartis: Consultancy; Curis: Consultancy; BMS: Consultancy. Von Bubnoff:Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria. Stegelmann:Pfizer: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; GSK: Consultancy, Honoraria; MorphoSys: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; AOP Pharma: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria. Brümmendorf:Gilead: Consultancy, Speakers Bureau; Merck: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy, Honoraria, Patents & Royalties, Research Funding, Speakers Bureau; Pfizer: Consultancy, Honoraria, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau.
In this clinical phase 2b trial, ruxolitinib is used off-label for firstline treatment of patients with polycythemia vera (PV).
